<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:24407638;
mso-list-template-ids:1165676024;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:66729981;
mso-list-template-ids:605709574;}
@list l1:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2
{mso-list-id:206644341;
mso-list-template-ids:-1043814252;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:324284204;
mso-list-template-ids:-484676894;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4
{mso-list-id:707753583;
mso-list-template-ids:-1018526644;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:1111439624;
mso-list-template-ids:-652726082;}
@list l5:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-weight:bold;
mso-bidi-font-weight:bold;}
@list l5:level2
{mso-level-start-at:0;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level3
{mso-level-start-at:0;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level4
{mso-level-start-at:0;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level5
{mso-level-start-at:0;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level6
{mso-level-start-at:0;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level7
{mso-level-start-at:0;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level8
{mso-level-start-at:0;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level9
{mso-level-start-at:0;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6
{mso-list-id:1288245338;
mso-list-template-ids:-541803904;}
@list l6:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l6:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l6:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7
{mso-list-id:1897354480;
mso-list-template-ids:1719711038;}
@list l7:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l7:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l7:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8
{mso-list-id:2011909277;
mso-list-template-ids:-194367924;}
@list l8:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l8:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l8:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l9
{mso-list-id:2085906488;
mso-list-template-ids:-32100610;}
@list l9:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l9:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l9:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l9:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l9:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l9:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l9:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l9:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l9:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72" style="word-wrap:break-word">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Congressionally Directed Medical Research Programs: Open Funding Opportunities</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/arp"><span style="color:#0563C1">Autism</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due May 23.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/bmfrp"><span style="color:#0563C1">Bone Marrow Failure</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 29.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/kcrp"><span style="color:#0563C1">Kidney Cancer</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 2 and June 23 (depending on the program).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/lcrp"><span style="color:#0563C1">Lung Cancer</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due July 13.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/msrp"><span style="color:#0563C1">Multiple Sclerosis</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 23 and August 2 (depending on the program).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/nfrp"><span style="color:#0563C1">Neurofibromatosis</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 30.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/ocrp"><span style="color:#0563C1">Ovarian Cancer</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 22.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/pcarp"><span style="color:#0563C1">Pancreatic Cancer</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due July 8.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/prarp"><span style="color:#0563C1">Peer Reviewed Alzheimer's</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 17.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/prcrp"><span style="color:#0563C1">Peer Reviewed Cancer</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due May 25, July 12, and August 17 (depending on the program).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/prorp"><span style="color:#0563C1">Peer Reviewed Orthopaedic</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 16.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/pcrp"><span style="color:#0563C1">Prostate Cancer</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 2, July 7, and August 4 (depending on the program).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/rcrp"><span style="color:#0563C1">Rare Cancers</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 22 and July 18 (depending on the program).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/scirp"><span style="color:#0563C1">Spinal Cord Injury</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due May 23.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/tbdrp"><span style="color:#0563C1">Tick-Borne Disease</span></a>
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due May 26.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/tscrp"><span style="color:#0563C1">Tuberous Sclerosis Complex</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Pre-applications due June 30.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: 10
<i>business</i> days before submission to sponsor.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.wheneveryonesurvives.org/grant_application"><span style="color:#0563C1">When Everyone Survives Leukemia Research Foundation Grants</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation
is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of “<b>W</b>hen
<b>E</b>veryone <b>S</b>urvives”. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 1.</span></b><span style="font-family:Palatino">
<b><span style="color:red">Med-RA deadline to receive draft documents: May 16 due to Memorial Day holiday.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.gene.com/good/giving/corporate-giving/rfp-genentech-2022-innovation-fund"><span style="color:#0563C1">Genentech Corporate Giving: 2022 Health Equity & Diversity in STEM Innovation
Fund</span></a><b><o:p></o:p></b></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Health Equity and Diversity in STEM Innovation Fund invites proposals to support major priorities:
<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l5 level1 lfo1"><b><span style="font-family:Palatino">Health Equity:</span></b><span style="font-family:Palatino"> Increasing representation of communities of color in clinical research and eliminating inequities in care
delivery<o:p></o:p></span></li></ol>
<p class="MsoNormal"><span style="font-family:Palatino">Strong proposals will align with the following high-level outcomes:
<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-family:Palatino">Increase trust, engagement, and partnership between research institutions, hospitals/healthcare systems, and communities of color (including approaches that acknowledge
and repair historic and ongoing harms inflicted upon communities of color) <o:p>
</o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-family:Palatino">Increase enrollment and retention of patients of color in clinical research by expanding access and embedding effective and purposeful engagement practices
<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-family:Palatino">Advance the science of how “the social becomes biological”—how structural racism (not “biological race”) influences biological mechanisms—and the implications for clinical
research and care delivery <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-family:Palatino">Advance the knowledge of sustainable approaches to community-partnered care delivery (e.g., effective integration approaches, addressing cultural and operational differences
between health care and human services organizations and mitigating unintended consequences)
<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-family:Palatino">Improve access to, persistence in, and satisfaction with specialty care for patients of color
<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-family:Palatino">Begin to close inequities in health care outcomes between racial and ethnic groups
<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-family:Palatino">Develop and strengthen accountability measures to promote antiracism, diversity, equity and inclusion across health care systems and research institutions
<o:p></o:p></span></li></ul>
<ol style="margin-top:0in" start="2" type="1">
<li class="MsoNormal" style="mso-list:l5 level1 lfo1"><b><span style="font-family:Palatino">Workforce Diversity:</span></b><span style="font-family:Palatino"> Dismantling barriers to a diverse, inclusive and antiracist scientific and health care workforce<o:p></o:p></span></li></ol>
<p class="MsoNormal"><span style="font-family:Palatino">Strong proposals will align with the following high-level outcomes:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l4 level1 lfo3"><span style="font-family:Palatino">Increase recruitment, retention, well-being and advancement of the next generation of diverse and antiracist scientific and medical talent
<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo3"><span style="font-family:Palatino">Develop and test cutting-edge approaches to scientific and medical training that center diversity, inclusion and antiracism
<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo3"><span style="font-family:Palatino">Catalyze new types of sustainable partnerships and collaborations across sectors (e.g., academia and industry) to build greater alignment, co-develop solutions and redirect
funding flows that enable greater diversity in the scientific and health care workforce
<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 10.</span></b><span style="font-family:Palatino">
<b><span style="color:red">Med-RA deadline to receive draft documents: May 27<sup>th</sup> due to Memorial Day holiday.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.humanvaccinesproject.org/michelson-prizes/"><span style="color:#0563C1">Michelson Prizes: Human Vaccines Project</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Michelson Prizes: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance
<b>human immunology, vaccine discovery, and immunotherapy research</b> for major global diseases. The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding
of key immune processes that are fundamental to successful vaccine and immunotherapy development. The Michelson Prizes are awarding research that is highly innovative and impactful, with the potential to be applied across many diseases. While the Michelson
Prizes are focused on research in the fields of immunology, vaccine and immunotherapy discovery, applicants from the full spectrum of related disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science,
artificial intelligence/machine learning, biophysics, nanotechnology, etc., are encouraged to apply.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 26.</span></b><span style="font-family:Palatino">
<b><span style="color:red">Med-RA deadline to receive draft documents: June 13.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-143.html"><span style="color:#0563C1">National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders
or Alcohol Use Disorder (U01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will
develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative
candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or
Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents
and neurostimulation approaches to treat mental disorders or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. This FOA will also support applications proposing
preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and
viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 27, 2022; October 25, 2022; February 24, 2023; June 26, 2023; October 26, 2023; February 27, 2024; June 25, 2024; October 25, 2025; and February 24, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for June 2022 due date: June 14.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://static1.squarespace.com/static/5cc3c3f1b7c92c0d65ebff6d/t/62474e3a896daa6d346d4850/1648840250999/Gut+Biome+RFP+April+2022.pdf"><span style="color:#0563C1">TMCity Foundation: Investigating
the Gut-Brain Axis for Applications to Brain and Mental Health</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This RFP seeks to address the gaps in our knowledge of how the gut affects brain health, with the goal of harnessing that knowledge to bring about measurable improvements to our prevention and treatment
of neuropsychiatric diseases. In other words, our aim is to understand and improve brain health by advancing our understanding of the gut and its relationship to the brain. TMCity Foundation will make an expected 1-3 grants, up to $250,000.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 1.</span></b><span style="font-family:Palatino">
<b><span style="color:red">Med-RA deadline to receive draft documents: June 17.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-program" target="_blank"><span style="color:#0563C1">Alzheimer’s Drug Discovery Foundation: Drug Development
Program</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should
be structured to deliver a compound with strong potential for clinical and commercial application. This funding opportunity prioritizes novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia.
For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Stage of discovery:</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo4"><span style="font-family:Palatino">Preclinical pharmacokinetics (PK) and pharmacodynamics (PD) (primarily to inform dose selection for in vivo efficacy studies), as well as preliminary rodent tolerability
studies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo4"><i><span style="font-family:Palatino">In vivo</span></i><span style="font-family:Palatino"> efficacy or proof-of-concept studies in animal models of disease or aging, with a focus on direct and indirect
markers of target engagement and downstream pharmacologic effects<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo4"><b><span style="font-family:Palatino">Please note:</span></b><span style="font-family:Palatino"> Applications that focus on basic research (including target discovery), assay development, and screening to
identify hit compounds are not a priority for this RFP and will be withdrawn<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo4"><b><span style="font-family:Palatino">Please note:</span></b><span style="font-family:Palatino"> IND-enabling work and clinical trials are supported through the
<a href="https://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact">
<b><span style="color:#0563C1">Program to Accelerate Clinical Trials (PACT) RFP</span></b></a><o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Therapeutic modalities:</span></b><span style="font-family:Palatino"> Includes small molecules, biologics, gene therapies, antisense oligonucleotides, and stem cells. Development of novel devices or
delivery systems will not be considered for this RFP.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Drug mechanisms or modes of action:</span></b><span style="font-family:Palatino"> Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia
are considered high priority. These include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Epigenetics<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Inflammation<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Mitochondrial & metabolic function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Neuroprotection<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Proteostasis<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Synaptic activity and neurotransmitters<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Vascular function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><span style="font-family:Palatino">Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l9 level1 lfo5"><b><span style="font-family:Palatino">Please note:</span></b><span style="font-family:Palatino"> Anti-amyloid approaches (e.g. anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors)
and cholinesterase inhibitor proposals will not be considered.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Award Amount: </span></b><span style="font-family:Palatino">Up to $600,000 based on stage and scope of research. No IDC.<br>
<b>Award Duration: </b>One year with potential for follow-on funding.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due September 30, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: September 16.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="http://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact" target="_blank"><span style="color:#0563C1">Alzheimer’s Drug Discovery Foundation: Program to Accelerate Clinical Trials
(PACT)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying
and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and
cholinesterase inhibitor proposals will not be considered for this RFP.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Stage of development:</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">1. Early-stage human clinical trials including:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-family:Palatino">Phase 0 micro- or sub-therapeutic-dosing studies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-family:Palatino">Phase 1 trials in healthy subjects<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-family:Palatino">Biomarker-based proof-of-concept studies (generally phase 1b or phase 2a trials) designed to assess target engagement and downstream pharmacologic effects<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">2. Regulatory studies including:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l7 level1 lfo7"><span style="font-family:Palatino">Non-GLP and GLP pharmacology and toxicology studies, pre-formulation, and GMP manufacture required for investigational new drug (IND) and clinical trial authorization (CTA)
preclinical packages. Funding is available for preparation of traditional and exploratory IND applications<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l7 level1 lfo7"><span style="font-family:Palatino">Long-term toxicology studies to enable longer-term dosing in phase 2 trials<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l7 level1 lfo7"><span style="font-family:Palatino">GMP manufacturing and testing of clinical grade drug required to move into phase 2 or phase 3 trials<o:p></o:p></span></li></ul>
<p class="MsoNormal"><i><span style="font-family:Palatino">For clinical trial applications, if IND-enabling work is in progress, funding for clinical studies would be contingent upon an IND (or equivalent) being granted and full review of the data package.
</span></i><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Type of therapy:</span></b><span style="font-family:Palatino"> Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest
include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Drug mechanisms or modes of action:</span></b><span style="font-family:Palatino"> Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia
are considered high priority. These include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Epigenetics<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Inflammation<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Mitochondrial & metabolic function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Neuroprotection<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Proteostasis<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Synaptic activity and neurotransmitters<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Vascular function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><span style="font-family:Palatino">Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo8"><b><span style="font-family:Palatino">Please note:</span></b><span style="font-family:Palatino"> Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors)
and cholinesterase inhibitor proposals will not be considered<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Average Duration:</span></b><span style="font-family:Palatino"> Varies<br>
<b>Average Award:</b> Up to $3 million; no IDC<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due September 30, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: September 19.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline" target="_blank"><span style="color:#0563C1">Alzheimer’s Drug Discovery Foundation: Prevention
Beyond the Pipeline</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the
risk for dementia or cognitive decline. The Prevention Pipeline RFP supports:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l1 level1 lfo9"><b><span style="font-family:Palatino">Studies of Cognitive Decline and Risk Reduction:</span></b><span style="font-family:Palatino"> Cognitive decline through aging and health conditions has been linked
to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain
injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under “Expectations and Evaluation”.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo9"><b><span style="font-family:Palatino">Comparative Effectiveness Research:</span></b><span style="font-family:Palatino"> For many health conditions, physicians have a choice of clinically equivalent drugs.
Some of these drugs are being investigated for repurposing to treat Alzheimer’s or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to
generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see
Box 1 in the <a href="https://alzres.biomedcentral.com/articles/10.1186/s13195-016-0200-3">
<b><span style="color:#0563C1">ADDF 2016 position paper</span></b></a>). Methods may include randomized trials or epidemiology.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo9"><b><span style="font-family:Palatino">Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA):</span></b><span style="font-family:Palatino"> Epidemiological studies contribute
unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to supplements or medications. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate
epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis
of cohorts using a shared analysis script. <a href="https://www.alzdiscovery.org/research-and-grants/funding-opportunities/capa-consortium">
<b><span style="color:#0563C1">More information here.</span></b></a><o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-family:Palatino">Type of therapy:</span></b><span style="font-family:Palatino"> Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest
include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Drug mechanisms or modes of action:</span></b><span style="font-family:Palatino"> Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia
are considered high priority. These include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Epigenetics<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Inflammation<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Mitochondrial & metabolic function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Neuroprotection<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Proteostasis<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Synaptic activity and neurotransmitters<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Vascular function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><span style="font-family:Palatino">Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo10"><b><span style="font-family:Palatino">Please note:</span></b><span style="font-family:Palatino"> Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase
inhibitors) and cholinesterase inhibitor proposals will not be considered<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">Grants of up to $3,000,000 will be awarded for clinical trials based on stage and scope of research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due September 30, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: September 19.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-024.html"><span style="color:#0563C1">Policy and Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD) Healthcare Disparities:
Access, Utilization, and Quality (R01 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits Research Project Grant (R01) applications for projects designed to exploit variations (e.g., geographic, temporal) in social and health care policies
to employ experimental, quasi-experimental, or other innovative approaches to uncover mechanisms driving disparities in care (i.e., access, utilization, and quality) for persons living with Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due October 20, 2022.</span></b><span style="font-family:Palatino">
<b><span style="color:red">Med-RA deadline to receive draft documents: October 10.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.rwjf.org/en/library/funding-opportunities/2020/pioneering-ideas-2020-exploring-the-future-to-build-a-culture-of-health.html?rid=0034400001rm2ZLAAY&et_cid=2046258" target="_blank"><span style="color:#0563C1">Robert
Wood Johnson Foundation: Pioneering Ideas–Culture of Health</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">As our current reality underscores, we live in a dynamic world—where unforeseen global events; new technologies; scientific discoveries; changes in our climate, economy, demographics; and more—continually
shape where and how we live, learn, work and play. These changes will profoundly impact
<a href="https://www.rwjf.org/content/rwjf/en/library/research/2017/05/what-is-health-equity-.html">
<span style="color:#0563C1">health equity</span></a> in our society, from our individual health and the health of our families to the health of our communities. What dramatic changes might we see in the next 5 to 15 years? What can we do today to create a better,
more equitable tomorrow? We seek to answer these questions, anticipate the future, and support unconventional approaches and breakthrough ideas that can help lead the way to a future where everyone in the United States can live their healthiest life possible.
Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. We are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction;
Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. We want to hear from scientists, anthropologists,
artists, urban planners, community leaders—anyone, anywhere who has a new or unconventional idea that could alter the trajectory of health, and improve health equity and well-being for generations to come. The changes we seek require diverse perspectives and
cannot be accomplished by any one person, organization or sector.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Proposals accepted on a rolling basis.
<span style="color:red">Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>